EXPRESSION MUTANT P53 DEPENDING ON CHEMOSENSITIVITY OF WIDE-SPREAD FORMS OF OVARIAN CANCER
https://doi.org/10.51523/2708-6011.2009-6-2-6
Abstract
Negotiation of chemoresistance by means of molecular target biomarkers for the use of more effective drugs is a relevant problem of modern oncogynaecology. The aim of study is to research the level of p53 expression advanced ovarian cancer. The study group consisted of 80 advanced ovarian cancer patients which underwent medical treatment in National Cancer Center of N.N. Alexandrov of Belarus from 1999 to 2002 year. Identification of p53 expression was carried out with immunohistochemistry. P53 expression was revealed in 61,3 % of cases, meanwhile 67,3 % of chemoresistant cases and in 38,8 % chemosensitive cases. In two studies groups differences in density of staining, quantity p53 staining cells in point system, amount of points (Score) and also ultimate number of staining cells (p < 0,05, Mann-Whitney test) are statistically significant. The level of p53 expression is high in serous, endometrial and undifferent forms of chemoresistant group ovarian cancer.
References
1. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of literature / A. Gadducci [et al.] // Int. J. Gynecol. Cancer. - 2007. - Vol. 17. - P. 21-31.
2. Приказ Министерства здравоохранения РБ № 80 «Алгоритмы диагностики и лечения злокачественных новообразований». - Мн., 2007. - 327 с.
3. Злокачественные новообразования в Беларуси 1996-2006 гг. / род ред. А. А. Граковича, И. В. Залуцкого. - Мн.: БелЦМТ, 2007. - 179 с.
4. Практическая онкология: избранные лекции заболеваний / под ред. С. А. Тюляндина, В. М. Моисеенко. - СПб.: Центр ТОММ, 2004. - 784 с.
5. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance / Rebecca J. Liu [et al.] // Cancer Research. - 2002. - Vol. 62. - P. 924-931.
6. Р53 is a determinant of X-linked inhibitor of apoptosis protein / M. Fraser [et al.] // Akt-mediated chemoresistance in human ovarian cancer cells // Cancer research. - 2003. - Vol. 63. - P. 7081-7088.
7. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a gynecologic oncology group study / L. Havrilesky [et al.] // J. Clin. oncol. - 2003. - Vol. 21. - P. 3814-3825.
8. Evidence for a dose-response effect between p53 (but not p21WAF/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy / M. Levesque [et al.] // Clin. Cancer Res. - 2000. - Vol. 6. - P. 3260-3270.
9. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multi-centre studies / P. Graeff [et al.] // Br. J. Cancer. - 2006. - Vol. 95. - P. 627-633.
10. P53 gene status and response to platinum/paclitaxel-based chemotherapy in advancad ovarian carcinoma / C. Lavarino [et al.] // J. Clin. oncol. - 2000. - Vol. 18. - P. 3936-3945.
11. Molecular prognostic markers in ovarian cancer: toward patient - tailored therapy / A. P. G. Crigns [et al.] // Int. J. Gynecol. Cancer. - 2006. - Vol. 16. - P. 152-165.
Review
For citations:
Moysey A.V. EXPRESSION MUTANT P53 DEPENDING ON CHEMOSENSITIVITY OF WIDE-SPREAD FORMS OF OVARIAN CANCER. Health and Ecology Issues. 2009;(2):30-34. (In Russ.) https://doi.org/10.51523/2708-6011.2009-6-2-6
Views: 304
Email this article 